nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

08.09.2020 | Original Article – Cancer Research

Gemcitabine potentiates anti-tumor effect of resveratrol on pancreatic cancer via down-regulation of VEGF-B

verfasst von: Yinan Yang, Wencong Tian, Lei Yang, Qiong Zhang, Mengmeng Zhu, Yuansheng Liu, Jing Li, Liang Yang, Jie Liu, Yanna Shen, Zhi Qi

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

In our previous study, we discovered that resveratrol (RSV) had potential tumor-promoting effect on pancreatic cancer (PaCa) via up-regulation of VEGF-B. Therefore, we assumed that a pharmacological inhibitor of VEGF-B should potentiate the anti-tumor effect of RSV on PaCa.

Methods

Real-time PCR and western blotting were used to examine VEGF-B mRNA and protein levels. Cell viability and cell apoptosis were assessed by CCK-8 assay and flow cytometry analysis, respectively. PaCa cell-bearing nude mice were used to evaluate the anti-cancer effects of single treatment or co-administration of RSV and gemcitabine (GEM).

Results

We found that treatment with GEM alone dramatically decreased VEGF-B expression in comparison with control group, indicating that GEM is a potential pharmacological inhibitor of VEGF-B in PaCa. The co-administration of RSV and GEM significantly lowered expression of VEGF-B and increased phosphorylation level of GSK3β at Ser9 when compared to RSV alone treatment either in vitro or in vivo. Combination of RSV and GEM significantly increased cell death and apoptosis of PaCa cells in vitro and inhibited tumor growth in vivo in comparison with RSV or GEM alone treatment. Furthermore, we found that the anti-tumor effect in combination group was dramatically weakened after VEGF-B overexpressed in PaCa cells.

Conclusion

These results suggest that VEGF-B signaling pathway plays an important role in the development of PaCa and combination of GEM and RSV would be a promising modality for clinical PaCa therapy.

Alharris E, Alghetaa H, Seth R, Chatterjee S, Singh NP, Nagarkatti M, Nagarkatti P (2018) Resveratrol attenuates allergic asthma and associated inflammation in the lungs through regulation of miRNA-34a that targets FoxP3 in mice. Front Immunol 9:2992PubMedPubMedCentralCrossRef

Andreani C, Bartolacci C, Wijnant K, Crinelli R, Bianchi M, Magnani M et al (2017) Resveratrol fuels HER2 and ERα-positive breast cancer behaving as proteasome inhibitor. Aging (Albany NY) 9(2):508–523CrossRef

Anisimov A, Leppänen VM, Tvorogov D, Zarkada G, Jeltsch M, Holopainen T et al (2013) The basis for the distinct biological activities of vascular endothelial growth factor receptor-1 ligands. Sci Signal 6(282):ra52PubMedCrossRef

Anisimov A, Tvorogov D, Alitalo A (2013) Vascular endothelial growth factor-angiopoietin chimera with improved properties for therapeutic angiogenesis. Circulation 127(4):424–434PubMedCrossRef

Apte RS, Chen DS, Ferrara N (2019) VEGF in signaling and disease: beyond discovery and development. Cell 176(6):1248–1264PubMedPubMedCentralCrossRef

Bapiro TE, Richards FM, Goldgraben MA, Olive KP, Madhu B, Frese KK et al (2011) A novel method for quantification of gemcitabine and its metabolites 2’,2’-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC-MS/MS: comparison with (19)F NMR spectroscopy. Cancer Chemother Pharmacol 68(5):1243–1253PubMedPubMedCentralCrossRef

Bhardwaj A, Sethi G, Vadhan-Raj S, Bueso-Ramos C, Takada Y, Gaur U et al (2007) Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood 109(6):2293–2302PubMedCrossRef

Bry M, Kivelä R, Leppänen V-M, Alitalo K (2014) Vascular endothelial growth factor-B in physiology and disease. Physiol Rev 94(3):779–794PubMedCrossRef

Chen L, Yang S, Zumbrun EE, Guan H, Nagarkatti PS, Nagarkatti M (2015) Resveratrol attenuates lipopolysaccharide-induced acute kidney injury by suppressing inflammation driven by macrophages. Mol Nutr Food Res 59(5):853–864PubMedPubMedCentralCrossRef

Chen C, Zou LX, Lin QY, Yan X, Bi HL, Xie X et al (2019) Resveratrol as a new inhibitor of immunoproteasome prevents PTEN degradation and attenuates cardiac hypertrophy after pressure overload. Redox Biol 20:390–401PubMedCrossRef

Cheng L, Yan B, Chen K, Jiang Z, Zhou C, Cao J et al (2018) Resveratrol-induced downregulation of NAF-1 enhances the sensitivity of pancreatic cancer cells to gemcitabine via the ROS/Nrf2 signaling pathways. Oxid Med Cell Longev 2018:9482018PubMedPubMedCentral

Cole A, Frame S, Cohen P (2004) Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation event. Biochem J 377(Pt 1):249–255PubMedPubMedCentralCrossRef

Deus CM, Serafim TL, Magalhães-Novais S, Vilaça A, Moreira AC, Sardão VA et al (2017) Sirtuin 1-dependent resveratrol cytotoxicity and pro-differentiation activity on breast cancer cells. Arch Toxicol 91(3):1261–1278PubMedCrossRef

Elkin M, Orgel A, Kleinman HK (2004) An angiogenic switch in breast cancer involves estrogen and soluble vascular endothelial growth factor receptor 1. J Natl Cancer Inst 96(11):875–878PubMedCrossRef

Falkevall A, Mehlem A, Palombo I, Heller Sahlgren B, Ebarasi L, He L et al (2017) Reducing VEGF-B signaling ameliorates renal lipotoxicity and protects against diabetic kidney disease. Cell Metab 25(3):713–726PubMedCrossRef

Feng L, Ren J, Li Y, Yang G, Kang L, Zhang S et al (2019) Resveratrol protects against isoproterenol induced myocardial infarction in rats through VEGF-B/AMPK/eNOS/NO signalling pathway. Free Radic Res 53(1):82–93PubMedCrossRef

Folbergrová J, Ješina P, Kubová H, Otáhal J (2018) Effect of resveratrol on oxidative stress and mitochondrial dysfunction in immature brain during epileptogenesis. Mol Neurobiol 55(9):7512–7522PubMedCrossRef

Hagberg CE, Falkevall A, Wang X, Larsson E, Huusko J, Nilsson I et al (2010) Vascular endothelial growth factor B controls endothelial fatty acid uptake. Nature 464(7290):917–921PubMedCrossRef

Hagberg CE, Mehlem A, Falkevall A, Muhl L, Fam BC, Ortsäter H et al (2012) Targeting VEGF-B as a novel treatment for insulin resistance and type 2 diabetes. Nature 490(7420):426–430PubMedCrossRef

Hanrahan V, Currie MJ, Gunningham SP, Morrin HR, Scott PA, Robinson BA, Fox SB (2003) The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression. J Pathol 200(2):183–194PubMedCrossRef

Huminiecki L, Horbanczuk J (2018) The functional genomic studies of resveratrol in respect to its anti-cancer effects. Biotechnol Adv 36(6):1699–1708PubMedCrossRef

Jiang Z, Chen X, Chen K, Sun L, Gao L, Zhou C et al (2016) YAP inhibition by resveratrol via activation of AMPK enhances the sensitivity of pancreatic cancer cells to gemcitabine. Nutrients 8(10):546PubMedCentralCrossRef

Kim YN, Choe SR, Cho KH, Cho DY, Kang J, Park CG, Lee HY (2017) Resveratrol suppresses breast cancer cell invasion by inactivating a RhoA/YAP signaling axis. Exp Mol Med 49(2):e296PubMedPubMedCentralCrossRef

Kivelä R, Bry M, Robciuc MR, Räsänen M, Taavitsainen M, Silvola JMU et al (2014) VEGF-B-induced vascular growth leads to metabolic reprogramming and ischemia resistance in the heart. EMBO Mol Med 6(3):307–321PubMedPubMedCentralCrossRef

Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV et al (2016) Pancreatic cancer. Nat Rev Dis Primers 2:16022PubMedCrossRef

Matsumura N, Takahara S, Maayah ZH, Parajuli N, Byrne NJ, Shoieb SM et al (2018) Resveratrol improves cardiac function and exercise performance in MI-induced heart failure through the inhibition of cardiotoxic HETE metabolites. J Mol Cell Cardiol 125:162–173PubMedCrossRef

Minami K, Shinsato Y, Yamamoto M, Takahashi H, Zhang S, Nishizawa Y et al (2015) Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors. J Pharmacol Sci 127(3):319–325PubMedCrossRef

Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H et al (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350(12):1200–1210PubMedCrossRef

Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K et al (2013) Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA 310(14):1473–1481PubMedCrossRef

Reymond N, d'Água BB, Ridley AJ (2013) Crossing the endothelial barrier during metastasis. Nat Rev Cancer 13(12):858–870PubMedCrossRef

Rivière C, Pawlus AD, Mérillon JM (2012) Natural stilbenoids: distribution in the plant kingdom and chemotaxonomic interest in Vitaceae. Nat Prod Rep 29(11):1317–1333PubMedCrossRef

Samulitis BK, Pond KW, Pond E, Cress AE, Patel H, Wisner L et al (2015) Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors. Cancer Biol Ther 16(1):43–51PubMedCrossRef

Serpi R, Tolonen AM, Huusko J, Rysä J, Tenhunen O, Ylä-Herttuala S, Ruskoaho H (2011) Vascular endothelial growth factor-B gene transfer prevents angiotensin II-induced diastolic dysfunction via proliferation and capillary dilatation in rats. Cardiovasc Res 89(1):204–213PubMedCrossRef

Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69(1):7–34PubMedCrossRef

Sun S, Zhang M, Yang Q, Shen Z, Chen J, Yu B et al (2017) Resveratrol suppresses lipoprotein-associated phospholipase A2 expression by reducing oxidative stress in macrophages and animal models. Mol Nutr Food Res 61(10):1601112CrossRef

Tan L, Wang W, He G, Kuick RD, Gossner G, Kueck AS et al (2016) Resveratrol inhibits ovarian tumor growth in an in vivo mouse model. Cancer 122(5):722–729PubMedCrossRef

Tian W, Yang L, Liu Y, He J, Yang L, Zhang Q et al (2019) Resveratrol attenuates doxorubicin-induced cardiotoxicity in rats by up-regulation of vascular endothelial growth factor B. J Nutr Biochem 79:108132PubMedCrossRef

Xu CP, Xue XJ, Liang N, Xu DG, Liu FJ, Yu XS, Zhang JD (2014) Effect of chemoradiotherapy and neoadjuvant chemoradiotherapy in resectable pancreatic cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol 140(4):549–559PubMedCrossRef

Yang L, Yang L, Tian W, Li J, Liu J, Zhu M et al (2014) Resveratrol plays dual roles in pancreatic cancer cells. J Cancer Res Clin Oncol 140(5):749–755PubMedCrossRef

Yang L, Zhang Y, Zhu M, Zhang Q, Wang X, Wang Y et al (2016) Resveratrol attenuates myocardial ischemia/reperfusion injury through up-regulation of vascular endothelial growth factor B. Free Radic Biol Med 101:1–9PubMedCrossRef

Zhang YJ, Wen CL, Qin YX, Tang XM, Shi MM, Shen BY, Fang Y (2017) Establishment of a human primary pancreatic cancer mouse model to examine and investigate gemcitabine resistance. Oncol Rep 38(6):3335–3346PubMedPubMedCentral

Zhou C, Qian W, Ma J, Cheng L, Jiang Z, Yan B et al (2019) Resveratrol enhances the chemotherapeutic response and reverses the stemness induced by gemcitabine in pancreatic cancer cells via targeting SREBP1. Cell Prolif 52(1):e12514PubMedCrossRef

Titel: Gemcitabine potentiates anti-tumor effect of resveratrol on pancreatic cancer via down-regulation of VEGF-B
verfasst von: Yinan Yang
Wencong Tian
Lei Yang
Qiong Zhang
Mengmeng Zhu
Yuansheng Liu
Jing Li
Liang Yang
Jie Liu
Yanna Shen
Zhi Qi
Publikationsdatum: 08.09.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 1/2021
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-020-03384-7

Springer Medizin

Gemcitabine potentiates anti-tumor effect of resveratrol on pancreatic cancer via down-regulation of VEGF-B